ARTICLE | Company News
J&J unit seeks U.S. approval of Xarelto for ACS
December 30, 2011 1:31 AM UTC
Johnson & Johnson (NYSE:JNJ) unit Janssen Research & Development LLC submitted an sNDA to FDA for Xarelto rivaroxaban to reduce secondary cardiovascular events in patients with acute coronary syndrome...